Chinese Company Says Its COVID-19 Vaccine Should Be Available in U.S. in Early 2021

If it passes final round of human tests, SinoVac will apply to the FDA to sell CoronaVac vaccine

THURSDAY, Sept. 24, 2020 (HealthDay News) — A Chinese pharmaceutical company claims its COVID-19 vaccine should available by early next year for distribution in the United States and other countries.

If it passes its final round of human tests, SinoVac will apply to the U.S. Food and Drug Administration to sell the CoronaVac vaccine, company CEO Yin Weidong said Thursday, the Associated Press reported.

Tight rules in the United States, European Union, Japan, and Australia have historically blocked the sale of Chinese vaccines, but that could change, according to Yin.

“We are confident that our research of the COVID-19 vaccines can meet the standards of the U.S. and EU countries,” Yin said, the AP reported.

AP News Article

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Chinese Company Says Its COVID-19 Vaccine Should Be Available in U.S. in Early 2021

If it passes final round of human tests, SinoVac will apply to the FDA to sell CoronaVac vaccine